Nonlinear effects and effect modification at the participant-level in IPD meta-analysis part 2: methodological guidance is available.

Autor: Marlin N; Methodology Research Unit, Centre for Evaluation and Methods, Wolfson Institute of Population Health, Queen Mary University of London, 58 Turner Street, London E1 2AB, UK. Electronic address: n.marlin@qmul.ac.uk., Godolphin PJ; MRC Clinical Trials Unit at University College London, Institute of Clinical Trials and Methodology, 90 High Holborn, London WC1V 6LJ, UK., Hooper RL; Methodology Research Unit, Centre for Evaluation and Methods, Wolfson Institute of Population Health, Queen Mary University of London, 58 Turner Street, London E1 2AB, UK., Riley RD; Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, UK., Rogozińska E; MRC Clinical Trials Unit at University College London, Institute of Clinical Trials and Methodology, 90 High Holborn, London WC1V 6LJ, UK.
Jazyk: angličtina
Zdroj: Journal of clinical epidemiology [J Clin Epidemiol] 2023 Jul; Vol. 159, pp. 319-329. Date of Electronic Publication: 2023 May 03.
DOI: 10.1016/j.jclinepi.2023.04.014
Abstrakt: Objectives: To review methodological guidance for nonlinear covariate-outcome associations (NL), and linear effect modification and nonlinear effect modification (LEM and NLEM) at the participant level in individual participant data meta-analyses (IPDMAs) and their power requirements.
Study Design and Setting: We searched Medline, Embase, Web of Science, Scopus, PsycINFO and the Cochrane Library to identify methodology publications on IPDMA of LEM, NL or NLEM (PROSPERO CRD42019126768).
Results: Through screening 6,466 records we identified 54 potential articles of which 23 full texts were relevant. Nine further relevant publications were published before or after the literature search and were added. Of these 32 references, 21 articles considered LEM, 6 articles NL or NLEM and 6 articles described sample size calculations. A book described all four. Sample size may be calculated through simulation or closed form. Assessments of LEM or NLEM at the participant level need to be based on within-trial information alone. Nonlinearity (NL or NLEM) can be modeled using polynomials or splines to avoid categorization.
Conclusion: Detailed methodological guidance on IPDMA of effect modification at participant-level is available. However, methodology papers for sample size and nonlinearity are rarer and may not cover all scenarios. On these aspects, further guidance is needed.
Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests.
(Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: